AstraZeneca reports disappointing results from latest 'Lynparza' trial
AstraZeneca, alongside its partner MSD, announced high-level results from the phase 3 ‘GY004’ trial on Thursday, which examined the efficacy and safety of the potential new medicine ‘cediranib’ added to ‘Lynparza’, or olaparib, when compared to platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer.
AstraZeneca
12,026.00p
17:14 25/04/24
FTSE 100
8,078.86
17:14 25/04/24
FTSE 350
4,434.34
17:09 25/04/24
FTSE All-Share
4,387.94
16:49 25/04/24
Pharmaceuticals & Biotechnology
22,750.48
17:09 25/04/24
The FTSE 100 pharmaceuticals giant described ovarian cancer as the eighth most common cause of death from cancer in women worldwide.
It said the trial did not meet the primary endpoint in the intent-to-treat population of a “statistically significant improvement” in progression-free survival, with cediranib added to Lynparza compared to platinum-based chemotherapy.
Cediranib is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor, the company explained, which blocks the growth of blood vessels supporting tumour growth.
“Despite these disappointing results, we remain committed to expanding on the benefits already demonstrated with Lynparza for patients with advanced ovarian cancer,” said execitive vice-president of oncology research and development José Baselga.
“We will work closely with NRG Oncology and the NCI to review the full results to inform our ongoing research.”
AstraZeneca said the safety and tolerability profiles observed in GY004 were “generally consistent” with those known for each medicine.
At 0827 GMT, shares in AstraZeneca were down 3.85% at 6,687p.